| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch |
| 21 Jul 2026 |
8-K: Other Events
On July 21, 2026, Krystal Biotech, Inc. (the “Company”) filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801, the Company’s investigational gen... |
| 20 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 15, 2026, Krystal Biotech, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter. |
| 04 May 2026 |
8-K: Financial Statements and Exhibits
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch |
| 17 Feb 2026 |
8-K: Results of Operations and Financial Condition
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis |
| 23 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
(b) On December 22, 2025, Kirti Ganorkar gave notice of his resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”). Mr. Ganorkar’s decision to resign was due to time constraints arising from increa... |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch |
| 22 Oct 2025 |
8-K: Other Events
Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK® (beremagene geperpavec) in Japan for the treatment of dystrop... |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition
$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 |
| 25 Jul 2025 |
8-K: Regulation FD Disclosure
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa |
| 24 Jul 2025 |
8-K: Regulation FD Disclosure
July 2025 1 KB304 PEARL-2 Results for Dynamic Wrinkles of the Décolleté r e p l e n i s h r e s t o r e Exhibit 99.2 |
| 09 Jul 2025 |
8-K: Regulation FD Disclosure
© Copyright 2025 Krystal Biotech, Inc. All rights reserved. KB801 for Neurotrophic Keratitis First Patient Dosed Update July 2025 |
| 02 Jun 2025 |
8-K: Other Events
RESULTS ASCO2025 Annual Meeting ABSTRACT #2575 Inhaled KB707, a Novel HSV-based Immunotherapy, as a Monotherapy in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs: Efficacy and Safety Results from a Phase 1/2 Study We... |
| 19 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 16, 2025, Krystal Biotech, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter. |
| 13 May 2025 |
8-K: Regulation FD Disclosure
Expansion of an HSV-1-Based Gene Therapy Platform to Treat Hailey-Hailey and Darier Diseases Bruce Nmezi, Ph.D.1*; Mary Jane Duermeyer, B.S.1; Jorge Guzman-Lepe, M.D.1; Trevor J. Parry, Ph.D.1; Suma M. Krishnan, M.S.1 1Krystal Biotech, I... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
VYJUVEK approved in Europe for the treatment of DEB patients from birth |
Loading...